CD 10: A Novel Stromal Marker in Pathogenesis and Prognosis of Invasive Breast Carcinoma
Keywords:
CD 10 stromal marker, Invasive breast carcinoma, Immunohistochemistry
Abstract
BACKGROUND: Breast carcinoma is the major cause of mortality and morbidity in Indian women. Though breast carcinoma arises from epithelial cells, stroma also plays a very important role in the pathogenesis of carcinoma breast which is assessed by the stromal marker CD 10. AIM : To study the stromal expression of CD 10 in carcinoma breast and find its relationship with other prognostic markers and study the role of stroma in pathogenesis of breast carcinoma. MATERIALS AND METHODS: 50 cases of breast cancer were included in the study. H & E slides were retrieved, reviewed and IHC was done with a panel of markers which included ER, PR, HER2/neu and CD 10. Stromal expression of CD 10 in invasive breast carcinoma was noted and analysed in correlation with other prognostic markers. RESULTS: Significances in the stromal CD 10 expression was calculated in regard to ER, PR & HER2/neu. Higher the tumour grade, more was the CD 10 stromal expression. CONCLUSION: As per the study, it is mandatory to include CD 10 stromal marker along with the panel of epithelial markers in invasive breast carcinoma. CD 10 contributes a potential target for development of novel therapies.References
1. Sayantan HJ et al. CD 10-A new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis. Indian Journal of Pathology and Microbiology 2014; October-December 57(4): 530-536.
2. Ali Taghizadeh – Kermani et al. The stromal overexpression of CD10 in Invasive breast
Cancer and its association with clinicopathologic factors. Iranian journal of Cancer
Prevention 2014; 7(1): 17-21.
3. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10
expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor
negatvity, and higher grade. Mod Pathol 2007; 20: 84-9.
4. Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma: A new predictor of clinical outcome. Virchows Arch 2002;440:589-93.
5.Masaki T, Keiichi I, Masahiko K, Miki I. The stromal expression of CD10 in breast
carcinoma. J of Tokyo Med University 2001;59: 45-50.
6. College of American pathologists[certified]: Protocol for the examination of specimens
from patients with invasive carcinoma of the breast[Protocol web posting date: June 2012].
Available from: http://www.cap.org/apps/cap.portal-144 .
7.https://www.socscistatistics.com/tests/fisher/Default2.aspx .
8. Mageur-Sata V, Besancon R, Bacherlard- Cascales E. Concise review: Neutral
endopeptidase (CD10): A multifaceted environment actor in stem cells, physiological
mechanisms and cancer. Stem Cells 2011; 29: 389-96
9. Bacherlard- Cascales E, Chapellier M Delay E, Pochon G, Voeltzel T, Puisieux A et al. The CD10 enzyme is a key player to identify and regulate human mammary cells. Stem Cells
2010; 28: 1081-8.
10.Weil M, Itin A, Keshet E. A role for mesenchyme derived tachykinins in tooth and
mammary gland morphogenesis. Development 1995;121:2419-28.
11.Kenny AJ, O’ Hare MJ, Gusterson BA. Cell surface peptidases as modulators of growth
and differentiation. Lancet 1989; 2:785-7.
12. Smollich M, Gote M, Yip GW Yong ES, Kersting C,Fischgrabe J et al. On the role of
endothelin-converting enzyme-1(ECE-1) and neprilysin in human breast cancer. Breast
Cancer Res Treat 2007; 106:361-9.
13. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of
oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004; 17:646-52.
14. Ashish Nitin Dhande et al. Stromal expression of CD 10 in breast carcinoma and its correlation with clinicopathological parameters. South Asian Journal of Cancer. 2019;8(1): 18-21.
15. Tahani Louhichi et al. Stromal CD 10 expression in breast cancer correlates with tumour invasion and cancer stem cell phenotype. BMC Cancer. 2018; 18: 49.
16.Thomas S. Babu RJ, Agarwal K, Pari V, Jain M, Andley M et al. Effect of neoadjuvant chemotherapy on stromal CD 10 antigen in breast cancer – a preliminary study. Indian J cancer 2013;50:46-51.
2. Ali Taghizadeh – Kermani et al. The stromal overexpression of CD10 in Invasive breast
Cancer and its association with clinicopathologic factors. Iranian journal of Cancer
Prevention 2014; 7(1): 17-21.
3. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10
expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor
negatvity, and higher grade. Mod Pathol 2007; 20: 84-9.
4. Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma: A new predictor of clinical outcome. Virchows Arch 2002;440:589-93.
5.Masaki T, Keiichi I, Masahiko K, Miki I. The stromal expression of CD10 in breast
carcinoma. J of Tokyo Med University 2001;59: 45-50.
6. College of American pathologists[certified]: Protocol for the examination of specimens
from patients with invasive carcinoma of the breast[Protocol web posting date: June 2012].
Available from: http://www.cap.org/apps/cap.portal-144 .
7.https://www.socscistatistics.com/tests/fisher/Default2.aspx .
8. Mageur-Sata V, Besancon R, Bacherlard- Cascales E. Concise review: Neutral
endopeptidase (CD10): A multifaceted environment actor in stem cells, physiological
mechanisms and cancer. Stem Cells 2011; 29: 389-96
9. Bacherlard- Cascales E, Chapellier M Delay E, Pochon G, Voeltzel T, Puisieux A et al. The CD10 enzyme is a key player to identify and regulate human mammary cells. Stem Cells
2010; 28: 1081-8.
10.Weil M, Itin A, Keshet E. A role for mesenchyme derived tachykinins in tooth and
mammary gland morphogenesis. Development 1995;121:2419-28.
11.Kenny AJ, O’ Hare MJ, Gusterson BA. Cell surface peptidases as modulators of growth
and differentiation. Lancet 1989; 2:785-7.
12. Smollich M, Gote M, Yip GW Yong ES, Kersting C,Fischgrabe J et al. On the role of
endothelin-converting enzyme-1(ECE-1) and neprilysin in human breast cancer. Breast
Cancer Res Treat 2007; 106:361-9.
13. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of
oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004; 17:646-52.
14. Ashish Nitin Dhande et al. Stromal expression of CD 10 in breast carcinoma and its correlation with clinicopathological parameters. South Asian Journal of Cancer. 2019;8(1): 18-21.
15. Tahani Louhichi et al. Stromal CD 10 expression in breast cancer correlates with tumour invasion and cancer stem cell phenotype. BMC Cancer. 2018; 18: 49.
16.Thomas S. Babu RJ, Agarwal K, Pari V, Jain M, Andley M et al. Effect of neoadjuvant chemotherapy on stromal CD 10 antigen in breast cancer – a preliminary study. Indian J cancer 2013;50:46-51.
Published
2020-04-29
Issue
Section
Original Article
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
